Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

Literature DB >> 8494710

First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

A Rosen¹, P Sevelda, M Klein, K Dobianer, C Hruza, K Czerwenka, H Hanak, N Vavra, H Salzer, S Leodolter.

Abstract

Estimation of FGF-3 oncogene amplification in DNA samples extracted from paraffin embedded sections of 136 ovarian cancer samples was carried out by a quantitative PCR method. The aim of this study was to elucidate a possible association of FGF-3 copy numbers with established prognostic factors such as age, histology, FIGO stage, grading, postoperative residual tumour mass, ascites, hormone receptor content and preoperative CA 125 serum levels. In addition, correlation of FGF-3 amplification with overall survival of the patients was assessed. There was a borderline positive correlation between preoperative CA 125 serum levels and the degree of amplification of the FGF-3 gene (P = 0.06). A statistically significant association of FIGO-stage with FGF-3 copy number could be found (P = 0.008). No correlation between FGF-3 amplification and overall survival was noted. The data combine to suggest that FGF-3 is an indicator of aggressiveness of ovarian cancer.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1993 PMID： 8494710 PMCID： PMC1968420 DOI： 10.1038/bjc.1993.206

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

21 in total

1. Proto-oncogene amplification and human breast tumor phenotype.

Authors: J Adnane; P Gaudray; M P Simon; J Simony-Lafontaine; P Jeanteur; C Theillet
Journal: Oncogene Date: 1989-11 Impact factor: 9.867

2. A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA.

Authors: W Rychlik; R E Rhoads
Journal: Nucleic Acids Res Date: 1989-11-11 Impact factor: 16.971

3. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.

Authors: D J Zhou; H Ahuja; M J Cline
Journal: Oncogene Date: 1989-01 Impact factor: 9.867

4. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors: R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal: Science Date: 1988-01-29 Impact factor: 47.728

Review 5. Malpractice, informed consent, and the use of low osmolality contrast media.

Authors: J M Eisner; B J Casey
Journal: Conn Med Date: 1988-02

6. Potential oncogene product related to growth factors.

Authors: C Dickson; G Peters
Journal: Nature Date: 1987 Apr 30-May 6 Impact factor: 49.962

7. Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene.

Authors: G Casey; R Smith; D McGillivray; G Peters; C Dickson
Journal: Mol Cell Biol Date: 1986-02 Impact factor: 4.272

8. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2.

Authors: C Dickson; R Smith; S Brookes; G Peters
Journal: Cell Date: 1984-06 Impact factor: 41.582

9. Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors.

Authors: H J Grill; B Manz; O Belovsky; K Pollow
Journal: Oncology Date: 1984 Impact factor: 2.935

First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

1. Proto-oncogene amplification and human breast tumor phenotype.

2. A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA.

3. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease.

4. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Review 5. Malpractice, informed consent, and the use of low osmolality contrast media.

6. Potential oncogene product related to growth factors.

7. Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene.

8. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2.

9. Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors.

10. Amplification of the int-2 gene in primary human breast tumors.

1. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

2. Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer.

3. Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma.

4. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer.

5. Phenotypic consequences of lung-specific inducible expression of FGF-3.

6. Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker.

7. The expression of embryonic liver development genes in hepatitis C induced cirrhosis and hepatocellular carcinoma.